Connecting clinical and genomic data for patients with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The AIO-BNHO CONNECT platform is a national, observational research initiative that collects and analyzes clinical and genomic data from patients with advanced solid tumors, excluding certain lung cancers and mesothelioma. It aims to compile real-world data from various healthcare providers, including community hospitals and university hospitals, to enhance understanding of precision oncology in Germany. The platform includes a decentralized tissue repository for tumor specimens, which can be utilized in future research projects. Both retrospective and prospective data will be gathered, including information from deceased patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of advanced (i.e., locally advanced, inoperable, or metastatic) solid tumor, ineligible for curative surgery and/or curative systemic therapy
* Available results of commercial or non-commercial RNA- and/or DNA-based multi-gene NGS panels with \>30 genes analyzed; for non-commercial panels a list of all tested genes and multiple gene biomarkers (e.g., tumor mutational burden (TMB), microsatellite status) must be provided
* Age ≥ 18 years
* Signed and dated informed consent form (not applicable for inclusion of deceased patients)

Exclusion Criteria:

* Diagnosis of NSCLC/SCLC (C34) or mesothelioma (C45)
* NGS results older than two years at the date of patient inclusion

Where it's running

• Praxis für interdisziplinäre Onkologie & Hämatologie
  Freiburg im Breisgau, Baden-Wurttemberg, Germany Recruiting
• Medizinische Fakultät Mannheim der Universität Heidelberg
  Mannheim, Baden-Wurttemberg, Germany Not yet recruiting
• Klinikum der Universität München
  München, Bavaria, Germany Not yet recruiting

Study contacts

• Study coordinator: Marc Fischer
• Email: marc.fischer@aio-studien-ggmbh.de
• Phone: +49 30-8145344

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SGT003 in people with advanced solid tumors

  This early-phase study tests SGT003 in adults with advanced solid tumors to see if it is safe and tolerable and to get a first look at how it behaves in the body and any early signs of benefit.

  Recruiting Phase 1/2 Beijing Sungen Biomedical Technology Co., Ltd · Beijing, Beijing Municipality · NCT07811037

• YSCH-01 Nebulized Therapy for Lung Metastases in NSCLC and Advanced Solid Tumors

  A first-in-human, early-phase study tests a nebulized therapy called YSCH-01 to see if it is safe and shows any signs of benefit for adults with NSCLC or other cancers that have spread to the lungs.

  Recruiting Early Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07793500

• Personalized neoantigen-pulsed dendritic cell injections for malignant solid tumors

  This study tests personalized dendritic cell injections, with or without immune checkpoint inhibitors, to see if they are safe and can help patients with advanced solid tumors.

  Recruiting ZSky Biotech Inc · Qinhuangdao, Hebei · NCT07752953

• STX-003 in advanced solid tumors given by IV, alone or with pembrolizumab

  This study tests STX-003, given by IV, to see if it is safe and potentially effective for patients with advanced solid tumors, either alone or with pembrolizumab.

  Recruiting at 4 sites Phase 1/2 Strand Therapeutics Inc. · Scottsdale, Arizona and 3 other locations · NCT07751042

• ARV-6723 alone or with pembrolizumab in adults with advanced solid tumors

  This study tests ARV-6723, by itself or with pembrolizumab, to see if it is safe and could help the immune system fight advanced solid tumors in adults.

  Recruiting at 4 sites Phase 1/2 Arvinas Inc. · New York, New York and 3 other locations · NCT07749586

• BG-85738 alone or with other anticancer drugs in RAS-mutant advanced or metastatic solid tumors

  This study tests BG-85738, alone or with other cancer drugs, in adults whose solid tumors have RAS mutations and have progressed.

  Recruiting at 3 sites Phase 1 BeOne Medicines · South Brisbane, Queensland and 2 other locations · NCT07746141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.